Lorenz Schubert1, Lisa Fisecker1, Florian Thalhammer1, Heinz Burgmann1, Christoph Steininger2. 1. Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University Vienna, Vienna, Austria. 2. Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University Vienna, Vienna, Austria. christoph.steininger@meduniwien.ac.at.
Abstract
PURPOSE: Data on the efficacy, dosing and safety of letermovir for the compassionate therapeutic use of CMV infections are limited. METHODS: Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections. RESULTS: Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.7%). CONCLUSION: Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.
PURPOSE: Data on the efficacy, dosing and safety of letermovir for the compassionate therapeutic use of CMV infections are limited. METHODS: Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections. RESULTS:Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.7%). CONCLUSION:Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.
Authors: D R Kaul; S Stoelben; E Cober; T Ojo; E Sandusky; P Lischka; H Zimmermann; H Rubsamen-Schaeff Journal: Am J Transplant Date: 2011-05 Impact factor: 8.086
Authors: Francisco M Marty; Per Ljungman; Roy F Chemaly; Johan Maertens; Sanjeet S Dadwal; Rafael F Duarte; Shariq Haider; Andrew J Ullmann; Yuta Katayama; Janice Brown; Kathleen M Mullane; Michael Boeckh; Emily A Blumberg; Hermann Einsele; David R Snydman; Yoshinobu Kanda; Mark J DiNubile; Valerie L Teal; Hong Wan; Yoshihiko Murata; Nicholas A Kartsonis; Randi Y Leavitt; Cyrus Badshah Journal: N Engl J Med Date: 2017-12-06 Impact factor: 91.245
Authors: Nicholas Turner; Andrew Strand; Dilraj S Grewal; Gary Cox; Sana Arif; Arthur W Baker; Eileen K Maziarz; Jennifer H Saullo; Cameron R Wolfe Journal: Antimicrob Agents Chemother Date: 2019-02-26 Impact factor: 5.191
Authors: Per Ljungman; Michael Boeckh; Hans H Hirsch; Filip Josephson; Jens Lundgren; Garrett Nichols; Andreas Pikis; Raymund R Razonable; Veronica Miller; Paul D Griffiths Journal: Clin Infect Dis Date: 2016-09-28 Impact factor: 9.079
Authors: Cameron M Douglas; Richard Barnard; Daniel Holder; Randi Leavitt; Diane Levitan; Maureen Maguire; David Nickle; Valerie Teal; Hong Wan; Dirk C J G van Alewijk; Leen-Jan van Doorn; Sunwen Chou; Julie Strizki Journal: J Infect Dis Date: 2020-03-16 Impact factor: 5.226
Authors: Tobias B Polak; David G J Cucchi; Joost van Rosmalen; Carin A Uyl-de Groot; Jonathan J Darrow Journal: Front Pharmacol Date: 2022-05-23 Impact factor: 5.988